Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sonus Pharma (SNUS) ? Opinions -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (369)	9/4/2007 3:31:26 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 384

Sonus Pharma (SNUS) October implied volatility above 200 into data 7:20 AM EDT September 4, 2007 Sonus Pharma (Nasdaq: SNUS) : SNUS's TOCOSOL paclitaxel (TP) Phase 3 metastatic breast cancer top-line efficacy (overall response rate) and safety study data is expected in late September. SNUS closed at $4.32. SNUS October option implied volatility of 205 is above its 6-month average of 142 according to Track Data. Paul Foster